Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond

Durvalumab is the first approved adjuvant immunotherapy agent for patients with stage III NSCLC treated with concurrent chemoradiotherapy and is associated with improved overall survival. In order to minimise the number of hospital visits for patients receiving durvalumab during the COVID-19 pandemi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Joshi, Kroopa, Muhith, Abdul, Obeid, Mariam, Milner-Watts, Charlotte, Yousaf, Nadia, Popat, Sanjay, Davidson, Michael, Bhosle, Jaishree, O’Brien, Mary, Minchom, Anna
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier B.V. 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086258/
https://ncbi.nlm.nih.gov/pubmed/33965281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2021.04.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados